Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Langer/Twincraft

This article was originally published in The Rose Sheet

Executive Summary

Medical and therapeutic skincare company Langer will expand into additional personal care categories with its acquisition of private label manufacturer Twincraft early next year, firm states in Nov. 14 release. Valued at $26.7 mil., the transaction is expected to close in the first quarter of 2007, Langer says. The acquisition of Twincraft, producer of specialty bar soap, will bring Langer into the health and beauty, amenities, mass and direct marketing channels, firm notes. The soap manufacturer grossed revenues of approximately $27.1 mil. for fiscal year 2005. For the nine months ended Sept. 30, the firm reported revenues of $20.7 mil. Twincraft President and CEO Peter Asch is expected to join Langer's board of directors. The firm employs approximately 200 people in its Winooski and Essex Junction, Vt., locations. The business is expected to remain in Vermont...

You may also be interested in...



Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.

Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus

Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.

Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel

Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.


UsernamePublicRestriction

Register

RS014370

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel